Study search
Go straight to the source
Search PubMed, Europe PMC and ClinicalTrials.gov from one box. Results come from the indexes themselves, newest first, each linked to its original record.
Amiravo's reviewed summary: Orforglipron research reference →
146 records · showing 25 · open this search in PubMed
- PubMedRandomized Controlled TrialMulticenter StudyClinical Trial, Phase IIIOrforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026 Dec 20
- PubMedStudy design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension.American journal of preventive cardiology · 2026 Dec
- PubMedOrforglipron alleviates aortic aneurysm and dissection via inhibiting WNT5A noncanonical signaling.Biochemical pharmacology · 2026 Nov
- PubMedOral Versus Injectable Incretin-Based Anti-Obesity Therapies: An Integrated Computational and Evidence-Based Comparison of Orforglipron, Semaglutide, and Tirzepatide.Omics : a journal of integrative biology · 2026 Oct 20
- PubMedEstablishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes.Lancet (London, England) · 2026 Oct 17
- PubMedRandomized Controlled TrialClinical Trial, Phase IIIMulticenter StudyCardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.Lancet (London, England) · 2026 Oct 17
- PubMedQualitative Exit Interviews to Characterize the Positive Treatment Experiences of Patients in the Phase III Trial of Orforglipron Versus Oral Semaglutide for the Treatment of Type 2 Diabetes.The patient · 2026 Oct 16
- PubMedReviewOral Obesity Medicines in the Era of Cardiovascular-Kidney-Metabolic Syndrome (CKM): Beyond Weight Loss Toward Disease Modification.Drug design, development and therapy · 2026
- PubMedReviewGastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026 Oct
- PubMedSystematic ReviewReviewEfficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.Annals of internal medicine · 2026 Oct
- PubMedSafety and tolerability of orforglipron in Japanese people with type 2 diabetes.The lancet. Diabetes & endocrinology · 2026 Oct
- PubMedRandomized Controlled TrialMulticenter StudyClinical Trial, Phase IIILong-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial.The lancet. Diabetes & endocrinology · 2026 Oct
- PubMedReviewOrforglipron: First Approval.Drugs · 2026 Oct
- PubMedResearch Support, Non-U.S. Gov'tClinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.Clinical pharmacology and therapeutics · 2026 Oct
- PubMedPositive modulation of glucagon-like peptide 1 (GLP-1) receptor by endogenous haemorphins with implications in glucose metabolism and diabetes.British journal of pharmacology · 2026 Sep 29
- PubMedReviewOral Small-Molecule GLP-1 Receptor Agonists: Lessons from Clinical Candidates and a Blueprint for Next-Generation Design.Journal of medicinal chemistry · 2026 Sep 24
- PubMedReviewOrforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment.The Annals of pharmacotherapy · 2026 Sep 18
- PubMedPreferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete-Choice Experiment (OPTIC).Diabetes, obesity & metabolism · 2026 Sep 17
- PubMedPredicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial.Diabetes, obesity & metabolism · 2026 Sep 17
- PubMedSystematic ReviewMeta-AnalysisEfficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.BMC endocrine disorders · 2026 Sep 15
- PubMedReviewObstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring.Clinical oral investigations · 2026 Sep 14
- PubMedReviewOrforglipron and the Kidney: A Promise or Disappointment? The Need for Trials Examining Renal Outcomes.American journal of nephrology · 2026 Sep 9
- PubMedReviewGLP-1 receptor agonists and ocular safety- Pharmacokinetic insights into ischemic optic neuropathy and diabetic retinopathy risk: A review.Biomolecules & biomedicine · 2026 Sep 7
- PubMedReviewOral Incretin-Based Therapies for Weight Management.Current atherosclerosis reports · 2026 Sep 4
- PubMedReviewRecent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
Queries go directly from your browser to NCBI, EMBL-EBI and ClinicalTrials.gov; Amiravo does not store them. Study-type labels come from the indexes and can be wrong. A record's presence says nothing about whether a compound works or is safe. PubMed data via NCBI E-utilities; see NCBI policies.